Loading patent…
AssigneeZonhon Biopharma Institute Inc.
InventorsBruce Yong MA, He WANG, Jun WANG, Chennan GE, Chenyang JIANG, Xiang YAO, Fang SUN, Tao ZHANG, Yu ZHUANG, Menghan ZHANG
Estimating the term…
Provided are low glycosylated kallikrein I with no or a small amount of glycosylation at the NFS sequence and polyethylene glycol modified product and pharmaceutical applications. KLK1 with lower glycosylation at NFS is more active than KLK1 with higher glycosylation at NFS. A recombinant KLK1 mutant without N-glycosylation at the NFS sequence is also provided, containing only two N-glycosylation sites at NMS and NHT. Glycosylation of the recombinant KLK1 mutant is relatively more consistent, the molecular weight of the product is relatively more homogeneous, the yield is higher, the purification process is simpler, and the biological activity is higher, and the quality is more controllable.
Low glycosylated kallikrein I or its derivative, which is primate kallikrein I containing three N-glycosylation sites of native kallikrein I at NMS, NHT and NFS, of which asparagine at NFS has no glycosylation or a small amount of glycosylation, “low glycosylated” or “small amount of glycosylation” means that the proportion of glycosylated asparagine at NFS is ≤10%, ≤9%, ≤8%, ≤7%, ≤6%, ≤5%, ≤4%, ≤3%, ≤2%, ≤1%, ≤0.5% or ≤0.1%.
Recombinant kallikrein I mutant or its derivative, which is primate kallikrein I with only two N-glycosylation sites.
Dependencies are inferred from the claim text.